One way to control AFib is to take rhythm control medication, which helps your heart return to and stay in a normal rhythm. Life with AFib has its challenges. But with the right treatment and ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

That's significant because the GI tract is the most common site of bleeding with DOACs, and this type of bleeding is the only one for which DOACs do not have a better risk profile ...

One of the most commonly used types of medication to prevent strokes is blood thinners. These medications reduce the risk of ...

How should one manage atrial fibrillation after these studies? I would suggest that it is worth one trial of cardioversion off rhythm-control medication. If atrial fibrillation returns I would opt ...

If you have atrial fibrillation, though ... If you have one of these, work with your doctor to get it under control and feel better.

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Management of AF from a rate control or rhythm control perspective has been studied via a meta-analysis of 5 randomized trials. 7 Rate control in combination with anticoagulation as front-line ...

In the AFFIRM trial, elderly patients (mean age, 70; 61% men) with minimally symptomatic atrial fibrillation (AF) and high risk for stroke were randomized to either a rate-control or a rhythm ...

Looking back, Kokomo resident Mike Beatty knew he had something as a teenager, but he couldn’t put a name to it. Whenever he’d overexert himself, he’d feel “different,” but it would go away with rest.